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1010Objective: Recent studies support the use of endovascular treatment for ruptured abdominal aortic aneurysms,
but few studies have examined the use of thoracic endovascular aortic repair (TEVAR) for ruptured descending
thoracic aortic aneurysm. We evaluated nationwide data regarding short-term outcomes of TEVAR and open
aortic repair (OAR) for ruptured descending thoracic aortic aneurysm.
Methods: From US Nationwide Inpatient Sample data, we identified 923 patients who underwent ruptured
descending thoracic aortic aneurysm repair in 2006–2008 and who had no concomitant aortic disorders. Of these
patients, 364 (39.4%) underwent TEVAR and 559 (60.6%) underwent OAR. Multivariable regression was used
to assess the effect of TEVAR versus OAR after adjusting for potential confounding factors. Outcomes assessed
were in-hospital mortality, complications, failure to rescue (defined as the mortality among patients in whom
a complication develops), and disposition. Backward stepwise logistic regression was used to identify indepen-
dent predictors of outcomes for each approach.
Results: Patients undergoing TEVAR were older (72  12 years vs 65  15 years; P< .001) and had
a higher Deyo comorbidity index (4.19  1.79 vs 3.14  2.05; P < .001) than patients undergoing
OAR. Unadjusted mortality was 23.4% (85/364) for TEVAR and 28.6% (160/559) for OAR. After risk
adjustment, the odds of mortality, complications, and failure to rescue were similar for TEVAR and
OAR (P> .1 for all), but patients undergoing TEVAR had a greater chance of routine discharge (odds ra-
tio [OR] ¼ 3.3; P< .001). An interaction was identified that linked hospital size and operative approach
with risk of complications (P<.001). In smaller hospitals, TEVAR was associated with lower complication
rates than OAR (OR ¼ 0.21; P< .05). Regression analysis revealed that smaller hospital size predicted
significantly higher rates of mortality (OR ¼ 2.4; P<.05), complications (OR ¼ 4.0; P<.005), and failure
to rescue (OR ¼ 51.12; P < .001) in those undergoing OAR but not in those undergoing TEVAR.
Preexisting renal disorders substantially increased mortality risk (OR ¼ 10.81; P< .001) and failure to
rescue (OR ¼ 309.54; P< .001) in patients undergoing TEVAR.
Conclusions: Nationwide data for ruptured descending thoracic aortic aneurysm reveal equivalent mortality,
complication rates, and failure to rescue for TEVAR and OAR but more frequent routine dischargewith TEVAR.
Unlike OAR outcomes, TEVAR outcomes were not poorer in smaller hospitals, where TEVAR produced fewer
complications than OAR. Therefore, TEVAR may be an ideal alternative to OAR for ruptured descending tho-
racic aortic aneurysm, particularly in small hospitals where expertise in OAR may be lacking and immediate
transfer to a higher echelon of care may not be feasible. (J Thorac Cardiovasc Surg 2011;142:1010-8)Thoracic endovascular aortic repair (TEVAR) has gained
popularity in the United States since the Food and Drug Ad-
ministration approved the first TEVAR endoprosthesis in
2005.1 Today, the technique is commonly used in patients
with suitable anatomy. Recent studies have shown the feasi-
bility and superior outcomes of TEVAR in single centers and
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adjusted mortality between 2005 and 2007.4 The use of TE-
VAR has expanded to several off-label indications, such as
dissections.5-8 Yet, the use of TEVAR in patients with
ruptured thoracic aneurysms has not been studied in detail,
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Abbreviations and Acronyms
FTR ¼ failure to rescue (defined as death
after a complication)
ICD-9-CM ¼ International Classification of
Diseases, Ninth Revision, Clinical
Modification
NIS ¼ Nationwide Inpatient Sample
OAR ¼ open aortic repair
OR ¼ odds ratio
rDTAA ¼ ruptured descending thoracic aortic
aneurysm
TEVAR ¼ thoracic endovascular aortic repair
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Daneurysm repair. Some single-center studies recently evalu-
ated the use of TEVAR for ruptured aneurysms,9,10 and
a population-based study showed that endovascular tech-
niques produced better results than open surgical repair for
ruptured abdominal aortic aneurysm.11
Compared with traditional open surgery, TEVAR has
been associated with a lower risk of a composite of death,
stroke, and paraplegia.12 Studies have found that for a rup-
tured descending thoracic aortic aneurysm (rDTAA), TE-
VAR produces results equivalent to those of open repair
whenever TEVAR is feasible.12,13 However, these studies
were restricted to a few centers of excellence and had
small patient cohorts. The relative utility of TEVAR in
elective cases is a topic of contention; population-based
studies suggest that endovascular approaches produce supe-
rior outcomes, whereas results from single centers of excel-
lence continue to favor the traditional open approach.2,14,15
Thus, little is known about TEVAR’s nationwide use and
outcomes as a treatment for rDTAA. Therefore, we
evaluated the in-hospital outcomes of TEVAR and open
procedures performed for rDTAA in the United States dur-
ing the initial 3-year period after Food and Drug Adminis-
tration approval. We also attempted to identify hospital
characteristics that affect outcomes.
MATERIALS AND METHODS
Data Source
We obtained patient data from the US Nationwide Inpatient Sample
(NIS), a database of hospital inpatient stays that is maintained by the
Agency for Healthcare Research and Quality as a part of the Healthcare
Cost and Utilization Project.16 Data from calendar years 2006 to 2008
were obtained. The NIS is the largest all-payer inpatient care database, rep-
resenting 90% of all hospital discharges from facilities in the United States
except government hospitals and Veterans Affairs medical centers. The
NIS has numerous internal quality assurance procedures for ensuring the
consistency and validity of data (available at: www.hcup-us.ahrq.gov/db/
quality.jsp).17 The NIS contains data on approximately 8 million hospital
stays annually from more than 1000 hospitals, although the exact number
varies slightly on an annual basis. Only data from participating states were
included; 38, 40, and 42 states participated in the NIS for the years 2006,The Journal of Thoracic and Car2007, and 2008, respectively. Weights based on sampling probabilities
for each stratum were used in the analysis to ensure that the hospitals stud-
ied were representative of all US hospitals.
The variables available in the NIS database include patient and hospital
demographics, hospital ownership, payer information, treating and con-
comitant diagnoses, inpatient procedures, in-hospital mortality, and hospi-
tal length of stay (ie, the date of admission to the date of discharge). The
NIS database also captures up to 15 International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic and
procedure codes per admission.18 The study was approved by the institu-
tional review board of the University ofMissouri-Columbia, which deemed
the study exempt from the informed consent requirement because the data
were nonidentifiable. The reported data conformed to the Healthcare Cost
and Utilization Project data-use agreement for the NIS. Additional infor-
mation about the NIS is available from the Agency for Healthcare Research
and Quality (available at: www.hcup-us.ahrq.gov/nisoverview.jsp).
Patient Selection
From the weighted NIS data for the calendar years 2006–2008, we used
the ICD-9-CM diagnosis and procedure codes (Appendix 1)18 to identify
all patients aged 18 years or older who had a diagnosis of rDTAA and
had undergone open aortic repair (OAR) or TEVAR in an urgent or emer-
gency admission. Patients with vasculitis, any connective tissue disorder,
gonadal dysgenesis, aortic dissection, or concomitant aneurysms in other
aortic segments were excluded. Patients who had undergone both OAR
and TEVAR were also excluded because we could not determine from
the available data whether thesewere intraoperative conversions or planned
staged procedures. The selection methods were similar to those used in
previous population-based TEVAR studies and excluded all patients who
underwent total cardiopulmonary bypass.2,19
The Deyo index was used to compare the 2 groups in terms of preoper-
ative morbidity.20 The Deyo index—a weighted comorbidity index modi-
fied from the Charlson comorbidity index—assesses 17 prespecified
comorbidities and is specifically designed to be used with administrative
databases, using more than 600 ICD-9-CM diagnosis codes to query
specific comorbid diagnoses.21 In previous surgical studies, we and other
investigators have demonstrated the feasibility of querying the NIS
database for cardiac, aortic, and vascular procedures.2,22-25 Up to 15
ICD-9-CM diagnosis codes were recorded per patient. These codes were
then used to produce a summary Deyo index score for each patient. The
Deyo index and its individual components were used for risk adjustment
in the statistical model.
Study End Points
The primary outcomes of interest for the present study were in-hospital
mortality (defined as death during the index hospitalization), complications,
failure to rescue (FTR; defined asmortality among patients in whom a com-
plication develops), and discharge disposition. FTR typically reflects hospi-
tal performance and quality of care; hospitals that provide the highest
qualityof care aremore capable of rescuingpatients inwhomacomplication
develops and therefore tend to have lower FTR rates. Discharge disposition
was classified as routine or nonroutine. A routine discharge was defined as
discharge to home without any sort of home health care, including home
intravenous medication therapy. Nonroutine discharges included discharge
to a skilled nursing or intermediate care facility or to homewith home health
care, as well as departure from the hospital against medical advice.
All-cause in-hospital morbidity was recorded according to the ICD-9-
CM diagnosis codes. The following morbidity categories were assessed:
intraoperative/procedure-related complications, postoperative infections,
neurologic complications, renal complications, respiratory complications,
deep vein thrombosis, and pulmonary embolism. Intraoperative and
procedure-related complications were defined as complications that oc-
curred during a procedure or that were directly related to technical aspects
of the procedure (Appendix 2).diovascular Surgery c Volume 142, Number 5 1011
TABLE 1. Baseline characteristics
Open repair
(n ¼ 559)
TEVAR
(n ¼ 364) P value
Age 64.8  15.2 72.1  11.6 <.001
Female sex 237 (42.4%) 181 (49.7%) .03
Caucasian race 269 (71.2%) 225 (78.9%) .02
Primary expected
payer—Medicare
325 (58.6%) 268 (73.6%) <.001
Household income .13
Lowest quartile 127 (23.3%) 69 (19.2%)
Second quartile 151 (27.7%) 98 (27.3%)
Third quartile 132 (24.2%) 111 (30.9%)
Highest quartile 135 (24.8%) 81 (22.6%)
Calendar year* <.001
2006 248 (69.3%) 110 (30.7%)
2007 132 (57.6%) 97 (42.4%)
2008 180 (53.3%) 158 (46.7%)
Large hospital bed size 436 (77.9%) 325 (89.0%) <.001
Chronic peripheral vascular
disease
20 (3.6%) 38 (10.4%) <.001
Prior myocardial infarction 10 (1.8%) 10 (2.7%) <.01
Congestive heart failure 94 (16.8%) 67 (18.4%) .53
Cerebrovascular disease 45 (8.1%) 35 (9.6%) .41
Dementia 10 (1.8%) 10 (2.7%) <.01
Chronic obstructive
pulmonary disease
100 (17.9%) 105 (28.8%) <.001
Rheumatoid disease 16 (2.9%) 10 (2.7%) .14
Peptic ulcer disease 10 (1.8%) 10 (2.7%) .01
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DStatistical Analysis
The Statistical Package for Social Sciences, version 18.0 (IBM SPSS,
Chicago, Ill), complex module was used for all statistical analyses. The
Student t test and chi-square statistics were computed to examine inter-
group differences in age, race, sex, patient income (by quartile, as encoded
in the NIS databases), Deyo index score, mortality, complications, hospital
length of stay, and discharge status. After univariate analysis, multivariable
analysis with hierarchic regression methods was performed.
Hierarchic logistic regression was used to examine the risk-adjusted as-
sociation of procedure type (OAR vs TEVAR) with in-hospital complica-
tions, mortality, FTR, and discharge disposition. From the results of this
overall regression analysis, an interaction analysis model was created to
identify the relationship between the use of TEVAR and the hospital
size. The NIS stratifies hospital bed size into 3 categories according to geo-
graphic region, hospital teaching status, and rural versus urban location.
The cutoff values used to define hospital size vary accordingly and can
be found on the Agency for Healthcare Research and Quality website
(http://www.ahrq.gov/).16 For ease of statistical analysis, the small and me-
dium bed size strata were combined into 1 group that was referred to as the
‘‘smaller bed size hospital’’ group. A subgroup analysis was then per-
formed to examine the impact of hospital bed size on each treatment group
(OAR and TEVAR). A backward stepwise regression model with individ-
ual components of the Deyo score was used for this subgroup analysis. The
iteration for the regression equation was run in a stepwise fashion accord-
ing to the change in the likelihood ratio. The model thus eliminated in
a stepwise fashion variables that did not contribute to the outcome until
the least change in likelihood ratio was achieved. Stringent variable inclu-
sion and exclusion thresholds (0.01 for ‘‘in’’ and 0.1 for ‘‘out’’) were used
to create a conservative model. This ensured that the model would summa-
rize the covariates in a conservative manner that would be unlikely to
produce significant results by chance.Chronic liver disease 10 (1.8%) 10 (2.7%) <.01
Diabetes mellitus 39 (7.0%) 47 (12.9%) <.01
Prior hemiplegia or paraplegia 36 (6.4%) 20 (5.5%) .56
Chronic renal disease 60 (10.7%) 49 (13.5%) .21
Malignancy 15 (2.7%) 10 (2.7%) .09
Deyo score 3.14  2.04 4.19  1.79 <.001
*Percentages are reported within each calendar year.RESULTS
Demographics and Baseline Characteristics
Of the 923 patients who underwent urgent intervention
for rDTAA, 364 (39.4%) underwent TEVAR and 559
(60.6%) underwent OAR. Several differences were noted
between the TEVAR and OAR groups (Table 1): Patients
in the TEVAR group were significantly older by 7 years,
and a higher proportion of them were women, white, and re-
ceiving Medicare. The TEVAR group had significantly
higher Deyo comorbidity scores than the OAR group. There
was a steady increase in the proportion of patients treated
with TEVAR during the study period, increasing from
31% in 2006 to 47% in 2008.Unadjusted Outcomes
Although there was a trend toward higher mortality in
the OAR group than in the TEVAR group, this difference
was not statistically significant (Table 2). There were no sig-
nificant differences in the overall complication rate or FTR
between the 2 groups, although patients who underwent
TEVAR had shorter hospital stays and a higher incidence of
routine home discharge than patients who underwent OAR.Logistic Regression: Risk-Adjusted Outcomes
Overall, female sex was a significant independent predic-
tor of overall complications (odds ratio [OR] ¼ 1.6),1012 The Journal of Thoracic and Cardiovascular Surmortality (OR ¼ 2.9), and FTR (OR ¼ 5.0) (P< .01 for
all) (Table 3). The use of TEVAR had no impact on mortal-
ity, FTR, or complication rates but was associated with a 3
times greater likelihood of routine home discharge
(P<.001). In contrast, smaller hospital bed size was asso-
ciated with higher FTR and complication rates (P< .05
and< .001, respectively), but not with significantly higher
mortality (P¼ .06), although there was a trend in that direc-
tion. To characterize this discrepancy, an interaction analy-
sis was performed.Interaction Analysis: Type of Procedure andHospital
Bed Size
An interaction term between hospital size and procedure
type was computed to determine whether these variables
had a synergistic beneficial or negative effect (Table 4).
The interaction factor was not significantly associated
with mortality or FTR but was associated with 77% less
complications (OR ¼ 0.23; P ¼ .004). The final OR forgery c November 2011
TABLE 2. Unadjusted outcomes
Open repair (n ¼ 559) TEVAR (n ¼ 364) Total (N ¼ 923) Chi-square/t P value
In-hospital mortality 160 (28.9%) 85 (23.4%) 245 (26.7%) 3.432 .064
Hemopericardium 41 (7.3%) 10 (2.7%) 41 (4.4%) 27.939 <.001
Open cardiac massage 15 (2.7%) 10 (2.7%) 15 (1.6%) 9.929 .002
Procedure-related
complications
120 (21.5%) 54 (14.8%) 174 (18.8%) 6.432 .011
Deep venous thrombosis 10 (1.8%) 10 (2.7%) 10 (1.1%) 7.720 .005
Infections 70 (12.5%) 62 (17.0%) 132 (14.3%) 3.660 .056
Mediastinitis 10 (1.8%) 10 (2.7%) 10 (1.1%) 6.571 .010
Neurologic complications 42 (7.5%) 25 (6.9%) 67 (7.3%) .131 .717
Pneumothorax 15 (2.7%) 10 (2.7%) 20 (2.2%) 1.784 .182
Respiratory complications 241 (43.0%) 229 (62.9%) 470 (50.9%) 34.872 <.001
Renal complications 141 (25.2%) 81 (22.3%) 222 (24.1%) 1.065 .302
Disposition 139 (25.1%) 120 (33.0%) 259 (28.2%) 6.729 .009
Overall complications 380 (68.0%) 242 (66.5%) 622 (67.4%) .224 .636
FTR 102 (18.4%) 62 (17.0%) 164 (17.9%) .285 .594
Length of stay 17.36 (28.0%) 14.47 (15.5%) 15.6 (21.4%) 2.008 .045
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lated as an exponent of the combined OR: Exp (1.442
0.099) ¼ 0.214. The calculated 95% confidence intervalTABLE 3. Overall regression analysis summary
Outcome Predictor OR
95% CI
P valueLower Upper
Mortality Female 2.94 1.99 4.36 <.001
Income quartile .62 .42 .91 .015
Smaller (vs larger)
hospital
1.58 .97 2.55 .064
TEVAR (vs OAR) 1.04 .71 1.52 .847
Deyo index .96 .87 1.06 .435
Caucasian race 1.92 1.21 3.04 .006
Complications Female 1.63 1.16 2.29 .005
Income quartile 1.30 .92 1.83 .138
Smaller (vs larger)
hospital
1.74 1.09 2.77 .021
TEVAR (vs OAR) .75 .53 1.06 .104
Deyo index 1.10 1.01 1.20 .030
Caucasian race .48 .31 .71 <.001
FTR Female 5.05 2.96 8.61 <.001
Income quartile .89 .55 1.42 .611
Smaller (vs larger)
hospital
3.44 1.97 6.04 <.001
TEVAR (vs OAR) .99 .62 1.57 .949
Deyo index 1.32 1.18 1.48 <.001
Caucasian race 1.33 .76 2.32 .319
Disposition Female .47 .32 .68 <.001
Income quartile 1.37 .94 2.00 .101
Smaller (vs larger)
hospital
.52 .31 .89 .017
TEVAR (vs OAR) 3.31 2.22 4.94 <.001
Deyo index .76 .68 .85 <.001
Caucasian race .66 .44 1.00 .050
CI, Confidence interval; TEVAR, thoracic endovascular aortic repair; OAR, open
aortic repair.
The Journal of Thoracic and Cardid not include 1, so the ORwas considered statistically sig-
nificant. An independent subgroup analysis was therefore
conducted to examine the impact of hospital size on the
OAR and TEVAR subgroups separately.
Postinteraction Subgroup Analysis
The final iteration of the backward stepwise regression
model (Table 5) for the TEVAR subgroup revealed that hos-
pital bed size was not predictive of any of the outcomes
(mortality, complications, or FTR). In contrast, coexisting
renal disease independently predicted mortality and FTR
in the TEVAR group. The same statistical analysis per-
formed on the OAR subgroup associated smaller hospital
bed sizewith greater odds of death, complications, and FTR.
DISCUSSION
This is the largest population-based study to evaluate the
outcomes of TEVAR for rDTAA in the United States. It is
interesting to note that this rather new technology has
been used for an emergency intervention in a substantial
number of patients. The TEVAR group differed from the
OAR group in that patients in the TEVAR group were older
(and, consequently, more likely to use Medicare) and had
more preoperative comorbidities. Nonetheless, most of
the overall unadjusted outcomes were not significantly dif-
ferent between groups, and the TEVAR group had a higher
proportion of routine home discharges than the OAR group.
In earliermulticenter and nationwide studies, TEVARhad
been shown to have superior outcomes toOAR even inmuch
older patients.1,2 However, its use in patients with rDTAA
had not been evaluated on a nationwide basis. Our analysis
revealed that, after risk adjustment, TEVAR has equivalent
outcomes to OAR but is associated with a greater chance
of routine home disposition. In the current era of
increasing health care costs, tightening budgets, and andiovascular Surgery c Volume 142, Number 5 1013
TABLE 4. Interaction analysis summary: Hospital bed size and
procedure type
Outcome Predictor OR
95% CI
P valueLower Upper
Mortality Female sex 2.94 1.99 4.35 <.001
Income quartile .63 .42 .92 .018
Smaller (vs larger)
hospital
1.47 .79 2.75 .225
Interaction factor* 1.19 .44 3.19 .733
TEVAR (vs OAR) 1.01 .67 1.53 .963
Deyo index .96 .87 1.06 .409
Caucasian race 1.92 1.21 3.04 .005
Complications Female sex 1.64 1.17 2.31 .005
Income quartile 1.22 .86 1.73 .260
Smaller (vs larger)
hospital
3.17 1.65 6.11 .001
Interaction factor* .24 .09 .62 .004
TEVAR (vs OAR) .90 .63 1.31 .601
Deyo index 1.12 1.03 1.23 .011
Caucasian race .46 .30 .69 <.001
FTR Female sex 5.10 2.98 8.72 <.001
Income quartile .87 .54 1.40 .569
Smaller (vs larger)
hospital
3.87 1.80 8.33 .001
Interaction factor* .78 .26 2.39 .664
TEVAR (vs OAR) 1.04 .62 1.75 .885
Deyo index 1.33 1.18 1.49 <.001
Caucasian race 1.32 .75 2.30 .335
CI, Confidence interval; TEVAR, thoracic endovascular aortic repair; OAR, open
aortic repair; FTR, failure to rescue. *Refers to the interaction between smaller
hospital bed size and the use of TEVAR.
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disposition constitutes an important advantage of TEVAR,
as does the shorter hospital stay associated with this
intervention.
Smaller hospital bed size was associated with greater
odds of developing a complication after surgical interven-
tion for rDTAA, yet the TEVAR technique by itself did
not increase complication rates. Rather, when TEVAR
was performed in smaller hospitals, the overall complica-
tion rate was lower. This synergistic effect was not seenTABLE 5. Backward stepwise regression: Final iterations of subgroup an
Predictor Outcome Group
Smaller (vs larger) hospital Mortality OAR
Complications OAR
FTR OAR
Smaller (vs larger) hospital Mortality TEVAR
Complications TEVAR
FTR TEVAR
Renal comorbidity Mortality TEVAR
FTR TEVAR
CI, Confidence interval; OAR, open aortic repair; FTR, failure to rescue; TEVAR, thoracic e
iteration.
1014 The Journal of Thoracic and Cardiovascular Surwith FTR or mortality, leading us to conclude that smaller
hospitals are still less capable than larger hospitals of han-
dling the complications of TEVAR or OAR. However, it
seems probable that TEVAR less often results in complica-
tions that would be difficult for small hospitals to handle.
More broadly, the interaction between hospital bed size
and the use of new technology such as TEVAR may be ad-
vantageous for smaller hospitals. This is because the cardiac
surgical, operating room, and intensive care unit personnel
at smaller hospitals may not have the skill sets and experi-
ence of their counterparts at larger hospitals, resulting in
poorer outcomes of OAR at smaller hospitals. Conversely,
small hospitals that perform TEVAR generally have a car-
diac catheterization laboratory or endovascular suite with
appropriate ancillary medical personnel who can provide
better support services than the personnel involved in
OAR procedures at the same hospital. Thus, it is probably
less difficult for a small hospital to handle straightforward
TEVAR than OAR procedures, so that the procedural as-
pects of TEVAR are performed better than those of OAR
in smaller hospitals.
The discrepancy in outcomes between TEVAR and OAR
performed at smaller hospitals was not seen in larger hospi-
tals, which seemed to be equally competent in both tech-
niques. Thus, TEVAR performed at smaller hospitals,
TEVAR performed at larger hospitals, and OAR performed
at larger hospitals all seem to produce similar outcomes,
whereas OAR performed at smaller hospitals produces
poorer outcomes. In light of these findings, it may be best
to avoid OAR at a smaller hospital, even if safe transfer to
a larger facility is not possible. If the patient’s aortic anat-
omy makes TEVAR feasible, and if personnel with endo-
vascular skills are available, using TEVAR in a smaller
hospital may be considered. Nonetheless, if transfer to
a larger facility can be accomplished safely, then transfer
is the most desirable course of action because of the possi-
bility that conversion from TEVAR to OAR will be neces-
sary. These considerations, along with the higher FTR and
mortality associated with TEVAR in patients with preexist-
ing renal disorders, complicate the workup of patientsalysis
OR
95% CI
P valueLower Upper
2.39 1.13 5.09 .023
3.96 1.78 8.79 .001
51.11 9.73 268.35 <.001
1.00 .30 3.30 .997*
.58 .21 1.56 .283*
1.05 .21 5.16 .951*
10.81 3.54 32.99 <.001
309.54 47.97 1997.15 <.001
ndovascular aortic repair. *Represents P value when covariate was excluded, not final
gery c November 2011
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suspected.13
Our study has certain limitations related to the source of
our data. First, we used an administrative database that is
subject to coding errors, because data entered by coders
are likely to be biased by the constraints of using only
ICD-9-CM codes for data reporting. However, using a cur-
rent clinical database that is more robust (eg, the Society of
Thoracic Surgeons database) was not an option, because
such databases have only recently begun to collect detailed
information on TEVAR procedures. In addition, cardiolo-
gists and vascular surgeons who perform TEVAR do not
participate in Society of Thoracic Surgeons data reporting,
making the NIS the only data source that captures all TE-
VAR procedures across the nation.
Second, the NIS database does not capture data regarding
readmissions, reinterventions, or long-term outcomes. For
these reasons and others, clinical decisions should not be
based solely on the outcomes reported in an administrative
database but should be supported by clinical judgment and
standards of care. Nonetheless, our study provides impor-
tant insight into the impact of TEVAR and hospital charac-
teristics on solid end points, such as mortality, length of
stay, and disposition.
It is also worth mentioning that of the smaller hospitals
represented in the study, only 22% (6/27) performed TE-
VAR for rDTAA; the rest performed OAR exclusively.
Some of these hospitals may have performed only OAR be-
cause, in the cases treated there, patient anatomy precluded
the use of TEVAR; however, it is probable that at least some
smaller hospitals performed OAR exclusively because they
did not have the necessary personnel and equipment to per-
form TEVAR. In addition, a smaller hospital that has the re-
sources needed to acquire TEVAR capability may have
more resources in general than other smaller hospitals and
may therefore be able to provide a higher quality of care.
This difference in hospital culture may have confounded
some of our findings.
Also, rDTAA constitutes a minute subset of the thoracic
aneurysms treated each year in theUnited States. As a result,
the number of patients with rDTAA in our study was rela-
tively small. Therefore, although adjusting for case volume,
surgeon volume, and surgeon specialty would have been
ideal, we could not have performed an adequately powered
statistical analysis if we had attempted to make such
adjustments.
In addition, the NIS database does not capture variables
related to the severity of rupture, such as whether patients
were in shock at the time of presentation or whether the rup-
ture was contained. Lack of such information made us un-
able to better stratify the patients for risk-adjusted
analysis. Also, the diagnosis of rupture is sometimes pre-
sumed when a pleural effusion is noted on imaging studies,
but this finding can indicate a sympathetic effusion ratherThe Journal of Thoracic and Carthan a true rupture. This distinction could not be made in
our patients.
The increased rate of respiratory and renal complications
we found in the TEVAR group is another surprising finding
that differs from published data.2 Although this finding may
be partly due to the higher comorbidity index in the patients
in the TEVAR group, it is also likely that patients in the
TEVAR group were in a more advanced state of shock on
admission. The administrative nature of the NIS prevented
us from better characterizing this anomalous finding. Like-
wise, the exact nature of postoperative neurologic compli-
cations cannot be determined from the NIS data.
Whereas the feasibility of TEVAR is subject to the anat-
omy of the aortic arch and the limitations of current endo-
vascular devices, almost any part of the aorta can be
repaired in an open fashion. The extent of the paradigm shift
we shall witness in the future will depend on improvements
in thoracic endograft designs, lessons learned from
population-based studies, experience from centers of excel-
lence, and surgeons’ ability to overcome learning curves. A
clinical study that evaluates the factors precluding the use of
urgent TEVAR for rDTAA would be compelling at this
juncture and would shed more light on the anatomic factors
that influence surgeon decision-making in these special
circumstances.
CONCLUSIONS
Smaller hospitals were associated with a higher overall
complication rate for any intervention for rDTAA. The
complication rate was lower for TEVAR procedures. Our
results suggest that smaller hospitals handle open repairs
less well than larger hospitals, so it would be prudent to
transfer patients with rDTAA to a large hospital when trans-
fer is feasible. However, any patient with a life-threatening
emergency is likely to be taken to the nearest hospital,
which may be smaller or larger, depending on its location,
local emergency medical services policy, and other factors.
rDTAA is rare and unlikely to be suspected before the pa-
tient reaches the emergency department. Valuable time
has probably already been lost by the time transport to a fa-
cility with expertise in thoracic aortic surgery is considered.
Unfortunately, safe transfer may not be possible in every
case, especially if the patient is in extremis, so smaller hos-
pitals may be forced to handle such complex cases on occa-
sion. If these hospitals possess endovascular facilities, then
the use of TEVAR may be a better alternative, given the
poorer outcomes typically seen with OAR in smaller hospi-
tals. Thus, our findings suggest the importance of conduct-
ing a randomized trial to evaluate the feasibility of
endovascular thoracic aortic intervention in smaller hospi-
tals. Such a trial would help to determine whether endovas-
cular suites in smaller hospitals are capable of handling
rDTAA cases and delivering outcomes similar to those of
larger centers. The trial could also reveal whether it woulddiovascular Surgery c Volume 142, Number 5 1015
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assessment criteria for potential TEVAR intervention
when rDTAA is suspected.
Although TEVAR should still be considered a highly ad-
vanced procedure that is best performed in a quaternary
center, it should be acknowledged that we are on the verge
of a paradigm shift. The steady increase in the adoption of
TEVAR for rDTAA over a short span of 3 years, the better
disposition rates of patients who have undergone this proce-
dure, and the use of TEVAR for rDTAA even in smaller hos-
pitals are noteworthy. The adoption of TEVAR for rDTAA
is likely to follow similar trends observed in the adoption of
endovascular approaches for treating ruptured abdominal
aneurysms.
Stephen N. Palmer, PhD, ELS, contributed to editing the
manuscript.
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Dr Thomas Gleason (Pittsburgh, Pa). I have no disclosures.
Dr Gopaldas, this was an excellent presentation and a well-written
article. I have a few questions.
First, your primary inclusion code was for ruptured thoracic an-
eurysm, which includes, of course, ascending, arch, and descend-
ing aortic aneurysms, each of which could significantly affect
treatment strategy. How did you ensure that only treatment of
descending thoracic aneurysms was included in your analysis? If
inclusion was based on trapping those in whom there was also
use of cardiopulmonary bypass, this would also not guarantee
exclusion of ascending or arch aneurysms.
Dr Gopaldas. The NIS database captures procedure codes, and
we did use the code that identifies cardiopulmonary bypass with
the use of an oxygenator. This is different from left heart bypass.
So we did exclude all patients who underwent cardiopulmonary
bypass. That ensured all patients with ascending and arch aneu-
rysms were excluded. The one downside to that, however, is
a subset of patients who underwent isolated descending repair
under circulatory arrest were probably excluded.
Now, if there was a way to include that particular subset, it
would have made our analysis stronger, but these are probably
a sicker subgroup of patients, and if they were included in the
model, it probably would have made TEVAR look even better.
Dr Gleason. How about cost? Were you able to establish any
estimates based on the NIS data used as to differences in hospital
cost per patient per group?
Dr Gopaldas.We actually did a cost analysis. I did not include
the slide. There was no statistically significant difference in cost
between TEVAR and open procedures, and even with the risk-ad-
justed model we did not find a difference. The approximate cost
was $20,000 for TEVAR and $19,000 for open repair, a $1000 dif-
ference. But, again, this was not statistically significant.gery c November 2011
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DDr Gleason. In the article, I note that respiratory complications
were actually significantly higher in the TEVAR group compared
with the open group, but despite this fact, length of stay and overall
mortality were lower in that group. Do you have any insight into
this apparent discrepancy?
DrGopoldas.That is a good question, and I was surprised when
we looked through the data. When we ran the analysis for the first
time, wewere surprised partly because our earlier results and stud-
ies on elective cases were exactly the opposite, where the respira-
tory complications were much lower. But the thing to look into and
pay attention to was that respiratory complications also include
pleural effusions or hemothorax and interventions for that. In an
elective case you probably don’t have to deal with much of those,
but when these patients come in with a rupture or potential rupture,
a lot of them have a pleural effusion. When they undergo an open
repair, they automatically have chest tubes placed, and so pleural
effusion is not documented separately. But then when they undergo
TEVAR and still have a persistent pleural effusion, it was docu-
mented for Diagnosis-Related Group billing purposes. They prob-
ably had a thoracentesis and chest tube, and as a result of that, the
percentage of respiratory complications was higher. When we
eliminated pleural effusion, the respiratory complications actually
were lower in the TEVAR subgroup.
Dr Gleason.We are not provided with the relative difference in
the number of open and TEVAR in the smaller and larger hospitals
in the article or presentation. I am curious whether there was a dif-
ference in the percentage of approach by size of hospital. Finally, if
this crude but large data set and analysis can be validated, what
conclusion should be drawnwith respect to the large centers in par-
ticular? It seems this may represent justification for more rather
than less use of open techniques in experienced centers if the mor-
tality and complication rates are shown to be equivalent, as you
have. Given that Dr Coselli’s group has one of the largest practices
in theworld for this disease set, how do you look at this data set and
respond at your own institution? How should this new information
change a large center’s practice?
Dr Gopaldas. Those are valid questions, and the point is well
taken. In cases performed at larger hospitals, 40% of them were
TEVAR, and in smaller hospitals it was approximately 25%, and
there was a statistically significant difference between them.
Now, to answer your question about how large centers should
look at this: I think the focus here was that the significant differ-
ence we noticed was in smaller centers where they had a tactical
advantage in performing TEVAR compared with open repair. Al-
though we did not show a difference in the outcomes in large hos-
pitals between TEVAR and open repair, the one thing we have to
look at is the disposition of these patients. There was a 3 times
greater chance that these patients actually went home after a TE-
VAR when they were in a large hospital. Although there is no dif-
ference in mortality, if you are looking at an elderly subgroup of
patients who are discharged and end up in a nursing home after
an open repair, you are dealing with a lot of problems down the
road, such as bedsores, pulmonary problems, and probably beingThe Journal of Thoracic and Cardebilitated and not going home. So I think TEVAR still has an ad-
vantage in that particular respect.
I did my cardiothoracic residency at Baylor, spent 3 years with
Dr Coselli, and was honored for having spent time there. The way
things are handled there is streamlined. There is a protocol in place
in the emergency department. So if anybody comes to the emer-
gency department and a question of an aortic issue is raised,
they are streamlined for a computed tomography angiogram rather
immediately. If the anatomy is feasible, we always prefer to use
TEVAR as our first option in these circumstances, because it is
quicker to do a femoral artery cutdown and tackle this as long as
the anatomy is feasible and allows that.
Now, I have been at theUniversity ofMissouri for less than1 year,
and we don’t have a hybrid suite; we are building one now. I have
been involved in approximately 12 cases, 2 of them were ruptured
TEVARs and the others were aortic transections. The one thing I
can tell frommy limited experience is that it is a lot easier in themid-
dle of the night towork with an endovascular team, because they are
in the hospital almost every day dealing with a cardiac catheter lab-
oratory emergency or peripheral vascular emergency. On the other
hand, if I have to mobilize the open heart team to come in, it takes
at least 1 to 1.5 hours. I would rather use that time to try an endovas-
cular approach while I get the open heart team in.
So with the availability of the technology and these data, TE-
VAR should be the ideal approach as long as you have a suitable
anatomy and the proper imaging studies.
Dr Gorav Ailawadi (Charlottesville, Va). Using the NIS to
compare 2 different techniques is not ideal because we really
don’t have any information about the anatomy. There is significant
selection bias. You cannot use NIS to compare 2 different proce-
dures and conclude that one is better than another because of these
significant limitations with the database. But my question relates
to the methodology of your inclusion/exclusion related to the pa-
tients that you called ‘‘hybrid.’’ You can use ICD-9-CM codes to
tell us if they had TEVAR or open. What did you do if they had
both? Did you exclude them because you said they were hybrid,
or what if they had a TEVAR and then underwent an open proce-
dure because of a complication or vice versa during the same hos-
pitalization? How can you distinguish this? There really isn’t
a great way to define which day during the hospitalization a partic-
ular procedure occurred. If you exclude these patients, then you ig-
nore complications that may have occurred with either approach.
Dr Gopaldas.We excluded all patients who had both procedures
done in the same hospital admission. TheNISwill allow you to iden-
tify the time difference between the 2 procedures, because it does
have a procedure day code. The problem, however, is that we can’t
tell if the patient had an open approach first and subsequently had
a problem such as a pseudoaneurysm or an anastomotic leak and
needed to have a TEVAR done, or if they had a TEVAR done first
and then it had to be converted to an open procedure later. Because
we couldn’t differentiate these 2 subcategories, we decided to ex-
clude all patients who had both procedures done in the same hospital
admission.diovascular Surgery c Volume 142, Number 5 1017
APPENDIX 1. ICD-9-CM codes used for inclusion/exclusion of study
group patients
Codes used for inclusion
441.1 Thoracic aneurysm, ruptured
39.73 Procedure code: Endovascular implantation of graft in
thoracic aorta
38.45 Procedure code: Resection of vessel with replacement;
thoracic aorta
Diagnosis codes used for exclusion
441.2 Thoracic aneurysm without mention of rupture
441.3 Abdominal aneurysm, ruptured
441.4 Abdominal aneurysm without mention of rupture
441.5 Aortic aneurysm of unspecified site, ruptured
441.6 Thoracoabdominal aneurysm, ruptured
441.7 Thoracoabdominal aneurysm without mention of
rupture
441.9 Aortic aneurysm of unspecified site without mention of
rupture
441.00 Aortic dissection, unspecified site
441.01 Aortic dissection, thoracic
441.02 Aortic dissection, abdominal
441.03 Aortic dissection, thoracoabdominal
446.0 Polyarteritis nodosa
446.1 Kawasaki disease
446.2 Hypersensitivity angiitis
446.3 Lethal midline granuloma
446.4 Wegener’s granulomatosis
446.5 Giant cell arteritis
446.6 Thrombotic microangiopathy
446.7 Takayasu disease; aortic arch arteritis
758.6 Turner syndrome; gonadal dysgenesis
759.82 Marfan syndrome
Procedure codes used for exclusion
39.61 Cardiopulmonary bypass auxiliary to open procedure
39.73þ38.45 Indicates conversion during or reintervention after
a thoracic aneurysm repair
39.71 Endovascular implantation of graft in abdominal aorta
38.44 Resection of vessel with replacement; abdominal aorta
APPENDIX 2. ICD-9-CM codes used to identify procedure-related
complications
423.0 Hemopericardium
997.1 Cardiac arrest or cardiorespiratory failure
996.0 Mechanical complication due to an implant/graft
996.74 Thrombosis, fibrosis, hemorrhage, or embolism due to
a vascular graft
998.31 Disruption of surgical wound
997.71 Vascular complications of mesenteric artery
998.0 Postoperative shock
998.11 Hemorrhage
998.12 Hematoma
998.13 Seroma
E878.2 Abnormal patient reaction/complication resulting directly
from a surgical procedure involving placement of
a prosthetic vascular graft
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